These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38102498)

  • 21. A Randomized, Phase III Study of Lenvatinib in Chinese Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.
    Zheng X; Xu Z; Ji Q; Ge M; Shi F; Qin J; Wang F; Chen G; Zhang Y; Huang R; Tan J; Huang T; Li S; Lv Z; Lin Y; Guo Z; Kubota T; Suzuki T; Ikezawa H; Gao M
    Clin Cancer Res; 2021 Oct; 27(20):5502-5509. PubMed ID: 34326132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer.
    Kiyota N; Schlumberger M; Muro K; Ando Y; Takahashi S; Kawai Y; Wirth L; Robinson B; Sherman S; Suzuki T; Fujino K; Gupta A; Hayato S; Tahara M
    Cancer Sci; 2015 Dec; 106(12):1714-21. PubMed ID: 26426092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
    Hewett Y; Ghimire S; Farooqi B; Shah BK
    J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimisation of treatment with lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.
    Capdevila J; Newbold K; Licitra L; Popovtzer A; Moreso F; Zamorano J; Kreissl M; Aller J; Grande E
    Cancer Treat Rev; 2018 Sep; 69():164-176. PubMed ID: 30032061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
    Brose MS; Smit JWA; Lin CC; Tori M; Bowles DW; Worden F; Shen DH; Huang SM; Tsai HJ; Alevizaki M; Peeters RP; Takahashi S; Rumyantsev P; Guan R; Babajanyan S; Ozgurdal K; Sugitani I; Pitoia F; Lamartina L
    Thyroid; 2022 Sep; 32(9):1059-1068. PubMed ID: 35950621
    [No Abstract]   [Full Text] [Related]  

  • 26. Effectiveness and toxicity of lenvatinib in refractory thyroid cancer: Dutch real-life data.
    Aydemirli MD; Kapiteijn E; Ferrier KRM; Ottevanger PB; Links TP; van der Horst-Schrivers ANA; Broekman KE; Groenwold RHH; Zwaveling J
    Eur J Endocrinol; 2020 Feb; 182(2):131-138. PubMed ID: 31751307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan.
    Takahashi S; Tahara M; Ito K; Tori M; Kiyota N; Yoshida K; Sakata Y; Yoshida A
    Adv Ther; 2020 Sep; 37(9):3850-3862. PubMed ID: 32676927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer.
    Suzuki C; Kiyota N; Imamura Y; Goto H; Suto H; Chayahara N; Toyoda M; Ito Y; Miya A; Miyauchi A; Otsuki N; Nibu KI; Minami H
    Head Neck; 2019 Sep; 41(9):3023-3032. PubMed ID: 31013380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.
    Jasim S; Iniguez-Ariza NM; Hilger CR; Chintakuntlawar AV; Ryder MM; Morris JC; Bible KC
    Endocr Pract; 2017 Oct; 23(10):1254-1261. PubMed ID: 28816536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem.
    Nervo A; Ragni A; Gallo M; Ferraris A; Fonio P; Piovesan A; Arvat E
    Thyroid; 2020 Feb; 30(2):229-236. PubMed ID: 31854230
    [No Abstract]   [Full Text] [Related]  

  • 31. Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib.
    Platini F; Cavalieri S; Alfieri S; Bergamini C; Resteghini C; Bottiglieri A; Colombo E; Mazzeo L; Licitra L; Paolini B; Seregni E; Locati LD
    Endocrine; 2021 Sep; 73(3):641-647. PubMed ID: 33797698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Fukuda N; Toda K; Ohmoto A; Wang X; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
    Anticancer Res; 2021 Mar; 41(3):1683-1691. PubMed ID: 33788766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ten years' real-life experience on the use of multikinase inhibitors in patients with advanced differentiated thyroid cancer.
    Jerkovich F; Capalbo S; Abelleira E; Pitoia F
    Endocrine; 2024 Aug; 85(2):817-826. PubMed ID: 38772990
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
    Jerkovich F; García Falcone MG; Pitoia F
    Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients.
    Fukuda N; Toda K; Udagawa S; Ohmoto A; Oki R; Suto H; Wang X; Hayashi N; Urasaki T; Sato Y; Nakano K; Ono M; Tomomatsu J; Mitani H; Takahashi S
    Endocrine; 2022 Apr; 76(1):70-77. PubMed ID: 35088293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
    Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
    Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
    Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
    Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study.
    Cheng L; Fu H; Jin Y; Sa R; Chen L
    Oncologist; 2020 Apr; 25(4):e668-e678. PubMed ID: 31957916
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.
    Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K
    Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.